<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d5">
    <sentence id="DDI-DrugBank.d5.s0" text="Few systemic data have been collected on the metabolism of WELLBUTRIN following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of WELLBUTRIN on the metabolism of other drugs.">
        <entity id="DDI-DrugBank.d5.s0.e0" charOffset="59-68"
            type="brand" text="WELLBUTRIN"/>
        <entity id="DDI-DrugBank.d5.s0.e1" charOffset="187-196"
            type="brand" text="WELLBUTRIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s1" text="Because bupropion is extensively metabolized, the coadministration of other drugs may affect its clinical activity.">
        <entity id="DDI-DrugBank.d5.s1.e0" charOffset="8-16" type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s2" text="In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme.">
        <entity id="DDI-DrugBank.d5.s2.e0" charOffset="31-39"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s2.e1" charOffset="69-84"
            type="drug_n" text="hydroxybupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s3" text="Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).">
        <entity id="DDI-DrugBank.d5.s3.e0" charOffset="63-72"
            type="brand" text="WELLBUTRIN"/>
        <entity id="DDI-DrugBank.d5.s3.e1" charOffset="124-135"
            type="drug" text="orphenadrine"/>
        <entity id="DDI-DrugBank.d5.s3.e2" charOffset="141-156"
            type="drug" text="cyclophosphamide"/>
        <ddi id="DDI-DrugBank.d5.s3.d0" e1="DDI-DrugBank.d5.s3.e0"
            e2="DDI-DrugBank.d5.s3.e1" type="int"/>
        <ddi id="DDI-DrugBank.d5.s3.d1" e1="DDI-DrugBank.d5.s3.e0"
            e2="DDI-DrugBank.d5.s3.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s4" text="The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes.">
        <entity id="DDI-DrugBank.d5.s4.e0" charOffset="4-22"
            type="drug_n" text="threohydrobupropion"/>
        <entity id="DDI-DrugBank.d5.s4.e1" charOffset="38-46"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s5" text="The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers.">
        <entity id="DDI-DrugBank.d5.s5.e0" charOffset="45-54"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d5.s5.e1" charOffset="83-91"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s6" text="Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.">
        <entity id="DDI-DrugBank.d5.s6.e0" charOffset="97-106"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d5.s6.e1" charOffset="133-141"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s6.e2" charOffset="147-162"
            type="drug_n" text="hydroxybupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s7" text="However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.">
        <entity id="DDI-DrugBank.d5.s7.e0" charOffset="105-123"
            type="drug_n" text="threohydrobupropion"/>
        <entity id="DDI-DrugBank.d5.s7.e1" charOffset="129-149"
            type="drug_n" text="erythrohydrobupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s8" text="While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).">
        <entity id="DDI-DrugBank.d5.s8.e0" charOffset="77-85"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s8.e1" charOffset="94-106"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d5.s8.e2" charOffset="109-121"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d5.s8.e3" charOffset="124-132"
            type="drug" text="phenytoin"/>
        <ddi id="DDI-DrugBank.d5.s8.d0" e1="DDI-DrugBank.d5.s8.e0"
            e2="DDI-DrugBank.d5.s8.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d5.s8.d1" e1="DDI-DrugBank.d5.s8.e0"
            e2="DDI-DrugBank.d5.s8.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d5.s8.d2" e1="DDI-DrugBank.d5.s8.e0"
            e2="DDI-DrugBank.d5.s8.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s9" text="Animal data indicated that bupropion may be an inducer of drug-metabolizing enzymes in humans.">
        <entity id="DDI-DrugBank.d5.s9.e0" charOffset="27-35"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s10" text="In one study, following chronic administration of bupropion, 100 mg 3 times daily to 8 healthy male volunteers for 14 days, there was no evidence of induction of its own metabolism.">
        <entity id="DDI-DrugBank.d5.s10.e0" charOffset="50-58"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s11" text="Nevertheless, there may be the potential for clinically important alterations of blood levels of coadministered drugs."/>
    <sentence id="DDI-DrugBank.d5.s12" text="Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.">
        <entity id="DDI-DrugBank.d5.s12.e0" charOffset="78-92"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d5.s12.e1" charOffset="107-116"
            type="group" text="tricyclics"/>
        <entity id="DDI-DrugBank.d5.s12.e2" charOffset="120-132"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d5.s12.e3" charOffset="135-149"
            type="drug" text="antiarrhythmics"/>
        <entity id="DDI-DrugBank.d5.s12.e4" charOffset="156-169"
            type="group" text="antipsychotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s13" text="Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.">
        <entity id="DDI-DrugBank.d5.s13.e0" charOffset="9-17"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s13.e1" charOffset="57-65"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s13.e2" charOffset="71-86"
            type="drug_n" text="hydroxybupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s14" text="In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.">
        <entity id="DDI-DrugBank.d5.s14.e0" charOffset="125-133"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s14.e1" charOffset="198-208"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d5.s14.e2" charOffset="247-257"
            type="drug" text="desipramine"/>
        <ddi id="DDI-DrugBank.d5.s14.d0" e1="DDI-DrugBank.d5.s14.e0"
            e2="DDI-DrugBank.d5.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s15" text="The effect was present for at least 7 days after the last dose of bupropion.">
        <entity id="DDI-DrugBank.d5.s15.e0" charOffset="66-74"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s16" text="Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.">
        <entity id="DDI-DrugBank.d5.s16.e0" charOffset="19-27"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s17" text="Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.">
        <entity id="DDI-DrugBank.d5.s17.e0" charOffset="32-40"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s17.e1" charOffset="112-126"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d5.s17.e2" charOffset="135-147"
            type="drug" text="nortriptyline"/>
        <entity id="DDI-DrugBank.d5.s17.e3" charOffset="150-159"
            type="drug" text="imipramine"/>
        <entity id="DDI-DrugBank.d5.s17.e4" charOffset="162-172"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d5.s17.e5" charOffset="175-184"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d5.s17.e6" charOffset="187-196"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d5.s17.e7" charOffset="199-208"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d5.s17.e8" charOffset="212-225"
            type="group" text="antipsychotics"/>
        <entity id="DDI-DrugBank.d5.s17.e9" charOffset="234-244"
            type="drug" text="haloperidol"/>
        <entity id="DDI-DrugBank.d5.s17.e10" charOffset="247-257"
            type="drug" text="risperidone"/>
        <entity id="DDI-DrugBank.d5.s17.e11" charOffset="260-271"
            type="drug" text="thioridazine"/>
        <entity id="DDI-DrugBank.d5.s17.e12" charOffset="275-287"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d5.s17.e13" charOffset="296-305"
            type="drug" text="metoprolol"/>
        <entity id="DDI-DrugBank.d5.s17.e14" charOffset="313-335"
            type="group" text="Type 1C antiarrhythmics"/>
        <entity id="DDI-DrugBank.d5.s17.e15" charOffset="344-354"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d5.s17.e16" charOffset="357-366"
            type="drug" text="flecainide"/>
        <ddi id="DDI-DrugBank.d5.s17.d0" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d1" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d2" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d3" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d4" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d5" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d6" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d7" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d8" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e9" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d9" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e10" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d10" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d11" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e12" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d12" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e13" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d13" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e14" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d14" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e15" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s17.d15" e1="DDI-DrugBank.d5.s17.e0"
            e2="DDI-DrugBank.d5.s17.e16" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s18" text="If bupropion is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index.">
        <entity id="DDI-DrugBank.d5.s18.e0" charOffset="3-11"
            type="drug" text="bupropion"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s19" text="MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .">
        <entity id="DDI-DrugBank.d5.s19.e0" charOffset="0-13"
            type="group" text="MAO Inhibitors"/>
        <entity id="DDI-DrugBank.d5.s19.e1" charOffset="74-82"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s19.e2" charOffset="103-115"
            type="group" text="MAO inhibitor"/>
        <entity id="DDI-DrugBank.d5.s19.e3" charOffset="117-126"
            type="drug" text="phenelzine"/>
        <ddi id="DDI-DrugBank.d5.s19.d0" e1="DDI-DrugBank.d5.s19.e1"
            e2="DDI-DrugBank.d5.s19.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s20" text="Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.">
        <entity id="DDI-DrugBank.d5.s20.e0" charOffset="0-7" type="drug" text="Levodopa"/>
        <entity id="DDI-DrugBank.d5.s20.e1" charOffset="13-22"
            type="drug" text="Amantadine"/>
        <entity id="DDI-DrugBank.d5.s20.e2" charOffset="119-127"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d5.s20.e3" charOffset="154-161"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d5.s20.e4" charOffset="166-175"
            type="drug" text="amantadine"/>
        <ddi id="DDI-DrugBank.d5.s20.d0" e1="DDI-DrugBank.d5.s20.e2"
            e2="DDI-DrugBank.d5.s20.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d5.s20.d1" e1="DDI-DrugBank.d5.s20.e2"
            e2="DDI-DrugBank.d5.s20.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s21" text="Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.">
        <entity id="DDI-DrugBank.d5.s21.e0" charOffset="18-27"
            type="brand" text="WELLBUTRIN"/>
        <entity id="DDI-DrugBank.d5.s21.e1" charOffset="66-73"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d5.s21.e2" charOffset="78-87"
            type="drug" text="amantadine"/>
        <ddi id="DDI-DrugBank.d5.s21.d0" e1="DDI-DrugBank.d5.s21.e0"
            e2="DDI-DrugBank.d5.s21.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s21.d1" e1="DDI-DrugBank.d5.s21.e0"
            e2="DDI-DrugBank.d5.s21.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s22" text="Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.">
        <entity id="DDI-DrugBank.d5.s22.e0" charOffset="65-74"
            type="brand" text="WELLBUTRIN"/>
        <entity id="DDI-DrugBank.d5.s22.e1" charOffset="94-107"
            type="group" text="antipsychotics"/>
        <entity id="DDI-DrugBank.d5.s22.e2" charOffset="116-130"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d5.s22.e3" charOffset="133-144"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d5.s22.e4" charOffset="156-163"
            type="group" text="steroids"/>
        <ddi id="DDI-DrugBank.d5.s22.d0" e1="DDI-DrugBank.d5.s22.e0"
            e2="DDI-DrugBank.d5.s22.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s22.d1" e1="DDI-DrugBank.d5.s22.e0"
            e2="DDI-DrugBank.d5.s22.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s22.d2" e1="DDI-DrugBank.d5.s22.e0"
            e2="DDI-DrugBank.d5.s22.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d5.s22.d3" e1="DDI-DrugBank.d5.s22.e0"
            e2="DDI-DrugBank.d5.s22.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s23" text="Low initial dosing and small gradual dose increases should be employed."/>
    <sentence id="DDI-DrugBank.d5.s24" text="Nicotine Transdermal System: .">
        <entity id="DDI-DrugBank.d5.s24.e0" charOffset="0-7" type="drug" text="Nicotine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s25" text="Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.">
        <entity id="DDI-DrugBank.d5.s25.e0" charOffset="0-6" type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d5.s25.e1" charOffset="114-120"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d5.s25.e2" charOffset="162-168"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d5.s25.e3" charOffset="192-201"
            type="brand" text="WELLBUTRIN"/>
        <ddi id="DDI-DrugBank.d5.s25.d0" e1="DDI-DrugBank.d5.s25.e2"
            e2="DDI-DrugBank.d5.s25.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s26" text="The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)">
        <entity id="DDI-DrugBank.d5.s26.e0" charOffset="19-25"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d5.s26.e1" charOffset="49-58"
            type="brand" text="WELLBUTRIN"/>
        <ddi id="DDI-DrugBank.d5.s26.d0" e1="DDI-DrugBank.d5.s26.e0"
            e2="DDI-DrugBank.d5.s26.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d5.s27" text="."/>
    <sentence id="DDI-DrugBank.d5.s28" text=""/>
</document>
